Influenza
Conditions
Brief summary
Each winter, viruses belonging to two kinds of influenza A (A/H1N1 & A/H3N2) and two kinds of influenza B (B/Yamagata & B/Victoria) can cause illness. Historically, the yearly influenza vaccine that was recommended in children was designed to protect against both kinds of influenza A but only one kind of influenza B. In a series of trials conducted between 2008-09 and 2010-11 (TITRE I, II, and IIB), the TITRE investigators measured antibody response to influenza B in children who were primed with two doses of trivalent inactivated influenza vaccine (TIV) containing B/Yamagata. Overall, the investigators found that 2 doses of vaccine containing B/Yamagata did not adequately prime children for response to the alternate B/Victoria antigen and that subsequent vaccine doses containing B/Victoria-lineage antigen strongly boosted antibodies to the B/Yamagata antigen that was introduced during first immunization priming, but with lower responses to B/Victoria. For the first time since 2009-10, the recommended B/Victoria component of the seasonal influenza vaccine has been changed, from B/Brisbane/60/2008 to B/Colorado/60/2007 for the coming 2018-19 season. The investigators thus have a unique opportunity to clarify lineage-specific influenza B responses in a well-characterized cohort of children originally primed to Yamagata. The investigators' main interest is to assess whether TITRE I children primed with two doses of B/Yamagata in 2008-09 have since or are now capable of achieving a sufficient antibody response to B/Victoria following a single dose of 2018-19 QIV, ten years after their initial TIV B/Yamagata priming exposure.
Interventions
BIOLOGICAL2018-19 quadrivalent inactivated influenza vaccine
A single age-appropriate dose of 2018-19 quadrivalent inactivated influenza vaccine
Sponsors
Vaccine Evaluation Center, Canada
McGill University Health Centre/Research Institute of the McGill University Health Centre
Institut National en Santé Publique du Québec
British Columbia Centre for Disease Control
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
10 Years to 13 Years
Healthy volunteers
No
Inclusion criteria
* Child previously completed the TITRE I study in British Columbia or Quebec; * Child is healthy (stable chronic conditions acceptable) as established by health assessment interview and verbal history-directed health examination; * Child is available and can complete all relevant procedures during the study period; * Parent or legal guardian is available and can be reached by phone during the study period; * Parent/guardian provides written informed consent; * Parent/guardian is fluent in English/French
Exclusion criteria
* Child has already received the 2018-19 seasonal (TIV or QIV) influenza vaccine; * Child has a bleeding condition that would prevent vaccine injection or blood collection; * Child has known or suspected immunodeficiency; * Child has a suspected or known anaphylactic reaction to any of the vaccine components used in this study; * Child has a health condition which, in the opinion of the investigator, would interfere with the evaluation or pose a health risk to the child; * Child has received immune globulin or other blood products within the prior six weeks; * Child has received injected or oral steroids within the prior six weeks defined by more than 1 week of immunosuppressants or immune modifying drugs (e.g. oral prednisolone \>0.5mL/kg/day or intravenous glucocorticoid steroid). Nasal, topical or inhaled steroids are allowed; * Child has received any live vaccine within 28 days of the study vaccine or is scheduled to receive live vaccine during the study period; * Child has received any inactivated vaccine within 14 days of the study vaccine; * Child is or will be enrolled in any other clinical trial of a drug, vaccine or medical device during the study period.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Seroprotection rate (SPR) for B/Victoria vaccine strains | Pre-vaccination | SPR based on hemagglutination inhibition (HI) assay for current (B/Colorado/06/2017-like) and prior (B/Brisbane/60/2008-like) Victoria lineage vaccine strains |
Secondary
| Measure | Time frame |
|---|---|
| Geometric mean titre (GMT) for B/Yamagata vaccine strains | Pre-vaccination |
| Geometric mean titre ratio (GMTR) for B/Yamagata vaccine strains | 4-6 weeks after receipt of QIV |
| Seroconversion rate (SCR) for B/Yamagata vaccine strains | 4-6 weeks after receipt of QIV |
| Seroprotection rate (SPR) for A/H1N1 vaccine strains | Pre-vaccination |
| Geometric mean titre (GMT) for A/H1N1 vaccine strains | Pre-vaccination |
| Geometric mean titre ratio (GMTR) for A/H1N1 vaccine strains | 4-6 weeks after receipt of QIV |
| Seroconversion rate (SCR) for A/H1N1 vaccine strains | 4-6 weeks after receipt of QIV |
| Seroprotection rate (SPR) for B/Yamagata vaccine strains | Pre-vaccination |
| Geometric mean titre (GMT) for A/H3N2 vaccine strains | Pre-vaccination |
| Geometric mean titre ratio (GMTR) for A/H3N2 vaccine strains | 4-6 weeks after receipt of QIV |
| Seroconversion rate (SCR) for B/Victoria vaccine strains | 4-6 weeks after receipt of QIV |
| Geometric mean titre (GMT) for B/Victoria vaccine strains | Pre-vaccination |
| Geometric mean titre ratio (GMTR) for B/Victoria vaccine strains | 4-6 weeks after receipt of QIV |
| Seroconversion rate (SCR) for A/H3N2 vaccine strains | 4-6 weeks after receipt of QIV |
| Seroprotection rate (SPR) for A/H3N2 vaccine strains | Pre-vaccination |
Countries
Canada
Outcome results
None listed